Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 8, 2008 - Issue 6
Submit an article Journal homepage
147
Views
34
CrossRef citations to date
0
Altmetric
Drug Profile

Imatinib mesylate for the treatment of chronic myeloid leukemia

Simona Soverini Department of Hematology & Oncological Sciences “Lorenzo e Ariosto Seràgnoli” University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. [email protected]
,
Giovanni Martinelli Department of Hematology & Oncological Sciences “Lorenzo e Ariosto Seràgnoli” University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. [email protected]
,
Ilaria Iacobucci Department of Hematology & Oncological Sciences “Lorenzo e Ariosto Seràgnoli” University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. [email protected]
&
Michele Baccarani Department of Hematology & Oncological Sciences “Lorenzo e Ariosto Seràgnoli” University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. [email protected]
Pages 853-864 | Published online: 10 Jan 2014

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sara De Santis, Cecilia Monaldi, Manuela Mancini, Samantha Bruno, Michele Cavo & Simona Soverini. (2022) Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. OncoTargets and Therapy 15, pages 103-116.
Read now
Anastasios Kyriazoglou & Constantinos Christopoulos. (2014) Severe dental erosion associated with imatinib mesylate therapy. Acta Oncologica 53:7, pages 988-990.
Read now

Articles from other publishers (32)

Noor E. Verhagen, Jan B. Koenderink, Nicole M. A. Blijlevens, Jeroen J. W. M. Janssen & Frans G. M. Russel. (2023) Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia. Pharmaceutics 15:11, pages 2535.
Crossref
Dongmei Gao, Guopeng Wang, Honghai Wu, JinHua Wu & Xiaoang Zhao. (2023) Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling. ACS Omega 8:15, pages 13741-13753.
Crossref
Maryam Shojaee, Pouya Soltan Khamsi, Mohammad Hosseini, Mehran Khodayari, Hasan Moghtaderi, Mir Razi Mousavi, Mohsen Farajpour & Shams Mohajerzadeh. (2022) A novel microscale platform for leukemia tumor treating field therapy and electrochemical screening. Microelectronic Engineering 257, pages 111738.
Crossref
Simona Soverini, Sara De Santis, Cecilia Monaldi, Samantha Bruno & Manuela Mancini. (2021) Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?. International Journal of Molecular Sciences 22:13, pages 7093.
Crossref
Abhijit Phukan, Prakas Kumar Mandal & Tuphan K. Dolai. (2020) Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India. Annals of Hematology 100:1, pages 85-96.
Crossref
Simona Soverini, Manuela Mancini, Luana Bavaro, Michele Cavo & Giovanni Martinelli. (2018) Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Molecular Cancer 17:1.
Crossref
Josephine T. Tauer, Bernadette A. S. Jäger, Anna Ulmer, Paula Geidel, Vera Girke, Lysann Kroschwald & Meinolf Suttorp. 2018. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy.
Simona Soverini, Michele Baccarani & Giovanni Martinelli. (2016) Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. The Lancet Haematology 3:12, pages e554-e555.
Crossref
Chevaun D. Morrison, Tressa M. Allington, Cheryl L. Thompson, Hannah L. Gilmore, Jenny C. Chang, Ruth A. Keri & William P. Schiemann. (2016) c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget 7:45, pages 72777-72794.
Crossref
Ivo VrobelHana JanečkováEdgar FaberKateřina Bouchalová, Kateřina MičováDavid FriedeckýTomáš Adam. (2016) Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma. Therapeutic Drug Monitoring 38:4, pages 516-524.
Crossref
Simona Soverini, Caterina De Benedittis, Manuela Mancini & Giovanni Martinelli. (2016) Best Practices in Chronic Myeloid Leukemia Monitoring and Management. The Oncologist 21:5, pages 626-633.
Crossref
Liang Guo, John HamreIIIIII, Myrtle Davis & Ralph E. Parchment. (2016) Human CD34+ progenitor hematopoiesis in liquid culture for in vitro assessment of drug-induced myelotoxicity. Toxicology in Vitro 31, pages 103-113.
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs 495 547 .
Simona Soverini, Caterina de Benedittis, Manuela Mancini & Giovanni Martinelli. (2015) Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15, pages S120-S128.
Crossref
Simona Soverini & Giovanni Martinelli. (2015) Interferon in CML: back to the past, or towards the future?. The Lancet Haematology 2:1, pages e8-e9.
Crossref
Inken Wierstra. 2013. 191 419 .
Simona SoveriniGiovanni Martinelli, Gianantonio Rosti, Ilaria Iacobucci & Michele Baccarani. (2012) Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis. Pharmacogenomics 13:11, pages 1271-1284.
Crossref
Mariko Carey, Amy Anderson, Rob Sanson-Fisher, Marita Lynagh, Chris Paul & Flora Tzelepis. (2012) How well are we meeting haematological cancer survivors’ preferences for involvement in treatment decision making?. Patient Education and Counseling 88:1, pages 87-92.
Crossref
Richard T. Silver. (2011) Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time?. The Oncologist 16:5, pages 554-558.
Crossref
Barbara Zehnbauer & Mona Nasser. 2011. Hematopathology. Hematopathology 293 323 .
Anna Eriksson, Martin Höglund, Elin Lindhagen, Anna Åleskog, Sadia Bashir Hassan, Carina Ekholm, Karin Fhölenhag, Annika Jenmalm Jensen, Agneta Löthgren, Martin Scobie, Rolf Larsson & Vendela Parrow. (2010) Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia. Biochemical Pharmacology 80:10, pages 1507-1516.
Crossref
Dylan M Bach, Joely A Straseski & William Clarke. (2010) Therapeutic drug monitoring in cancer chemotherapy. Bioanalysis 2:5, pages 863-879.
Crossref
Sabino Ciavarella, Annalisa Milano, Franco Dammacco & Franco Silvestris. (2010) Targeted Therapies in Cancer. BioDrugs 24:2, pages 77-88.
Crossref
Jessica C. Walrath, Jessica J. Hawes, Terry Van Dyke & Karlyne M. Reilly. 2010. 113 164 .
Baidehi Maiti, Sebouh Setrakian & Hamed A Daw. (2009) Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases Journal 2:1.
Crossref
Tressa M. Allington, Amy J. Galliher-Beckley & William P. Schiemann. (2009) Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors. The FASEB Journal 23:12, pages 4231-4243.
Crossref
V Giroux, J L Iovanna, S Garcia & J-C Dagorn. (2009) Combined inhibition of PAK7, MAP3K7 and CK2α kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Therapy 16:9, pages 731-740.
Crossref
Andrew J. Olaharski, Hirdesh Uppal, Matthew Cooper, Stefan Platz, Tanja S. Zabka & Kyle L. Kolaja. (2009) In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicology Letters 188:2, pages 98-103.
Crossref
Joydeep Mukherjee, Deepak Kamnasaran, Anand Balasubramaniam, Ivan Radovanovic, Gelareh Zadeh, Tim-Rasmus Kiehl & Abhijit Guha. (2009) Human Schwannomas Express Activated Platelet-Derived Growth Factor Receptors and c-kit and Are Growth Inhibited by Gleevec (Imatinib Mesylate). Cancer Research 69:12, pages 5099-5107.
Crossref
Li Su & WenFang Xu. (2009) Peptidomimetics and metalloprotease inhibitors as anticancer drugs. Science in China Series B: Chemistry 52:5, pages 535-548.
Crossref
David B. Jackson. (2009) Molecular perspectives on the non-responder phenomenon. Drug Discovery Today 14:7-8, pages 373-379.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:4, pages 253-260.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.